Payment overview · 2025
General Payments
$666.93
29 reported records · 14 companies
Healthcare provider profile · identity verified
Beth Ann Patel, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NEW SMYRNA BEACH, FL · NPI 1528383296
Verified facts
What the public records show
CMS Open Payments records show Beth Ann Patel, ARNP received $666.93 in general payments during 2025 across 29 reported records.
Axsome Therapeutics, Inc. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.41 | 14.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.96 | 13.8% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $87.28 | 13.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.77 | 10.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.16 | 10.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.82 | 9.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.67 | 7.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.83 | 4.3% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $22.94 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.00 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.75 | 2.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 2.6% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $15.52 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.44 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $649.55 | 28 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $94.41 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.96 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $87.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.76 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.16 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.83 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 495 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 75 |
| Methylprednisolone | Methylprednisolone | 196 | 130 |
| Montelukast Sodium | Montelukast Sodium | 195 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 65 |
| Bupropion Xl | Bupropion Hcl | 168 | 50 |
| Lorazepam | Lorazepam | 164 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 51 |
| Famotidine | Famotidine | 159 | 66 |
| Alprazolam | Alprazolam | 157 | 36 |
| Omeprazole | Omeprazole | 152 | 44 |
| Gabapentin | Gabapentin | 144 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 39 |
| Potassium Chloride | Potassium Chloride | 126 | 41 |
| Tramadol Hcl | Tramadol Hcl | 120 | 52 |
| Azithromycin | Azithromycin | 118 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 36 |
| Metformin Hcl | Metformin Hcl | 115 | 34 |
| Furosemide | Furosemide | 113 | 39 |
| Lisinopril | Lisinopril | 112 | 31 |
| Alendronate Sodium | Alendronate Sodium | 99 | 28 |
| Glipizide | Glipizide | 97 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 23 |
| Simvastatin | Simvastatin | 88 | 25 |
| Carvedilol | Carvedilol | 86 | 24 |
| Meloxicam | Meloxicam | 86 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 28 |
| Temazepam | Temazepam | 72 | 14 |
| Celecoxib | Celecoxib | 71 | 25 |
| Eliquis | Apixaban | 71 | 22 |
| Valsartan | Valsartan | 71 | 22 |
| Clonazepam | Clonazepam | 68 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Trazodone Hcl | Trazodone Hcl | 68 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 22 |
| Fenofibrate | Fenofibrate | 63 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 46 |
| Sertraline Hcl | Sertraline Hcl | 57 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 20 |
| Ondansetron Odt | Ondansetron | 56 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 17 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Allopurinol | Allopurinol | 42 | 13 |
| Ozempic | Semaglutide | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 14 |
| Estradiol | Estradiol | 38 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 17 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Bumetanide | Bumetanide | 30 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Diazepam | Diazepam | 27 | 12 |
| Buspirone Hcl | Buspirone Hcl | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | 12 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Prednisone | Prednisone | 25 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 13 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lamivudine Hbv | Lamivudine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.93 · 29 records | Axsome Therapeutics, Inc. | Auvelity, Brinsupri, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GIMOTI, Indigo System, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, WATCHMAN FLX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error